治还是不治?
研究通过析因设计的调查情景,探索影响轻症卒中患者阿替普酶治疗决策的临床因素。194名美国医生对150个情景评估给药可能性,治疗概率从6%到95%不等。四个主要因素仅解释决策总方差的不到15%,反映决策的高度变异性和复杂性。
要点
- 治疗概率随NIHSS评分从1分的24%升至5分的41%。
- 既往脑出血、近期抗凝、NIHSS和既往缺血性卒中四个因素合计占相对重要性的58%。
- 四个主要变量仅解释决策总方差的不到15%,决策变异性高。
核心结论
- 四个主要变量合计仅解释阿替普酶治疗决策相关总方差的不到15%,反映决策的高度变异性和复杂性。
- 未来研究应考虑其他变量,包括医生特征。
研究设计与样本
- 专家小组选定7个因素构建调查情景:NIHSS评分、NIHSS主要缺损区域、基线功能状态、既往缺血性卒中、既往脑出血、近期抗凝及治疗第一小时症状的时间模式。
- 采用部分析因设计(150个情景),提供7个主因素及NIHSS一阶交互作用的无混杂估计。
- 调查通过电子邮件发送至神经科医生、急诊医生的全国性组织及同事。
- 医生被随机分配至10组情景中的1组(每组15个情景),情景随机呈现。
- 医生以0至5分报告给予阿替普酶的主观可能性,量表类别锚定于从0%到100%的6个概率。
主要发现
- 单个情景的治疗平均概率范围为6%至95%。
- 治疗概率从NIHSS评分=1时的24%升至NIHSS评分=5时的41%。
- 联合统计模型解释了总观察反应方差的25%。
- 考虑所有可能交互作用的模型解释了30%的方差。
- 7个因素中有4个在联合模型中合计占总相对重要性的58%:既往脑出血(18%)、近期抗凝(17%)、NIHSS(13%)、既往缺血性卒中(10%)。
局限性
- 四个主要变量合计仅解释决策总方差的不到15%,反映高度变异性和复杂性。
- 联合统计模型仅解释总观察反应方差的25%。
- 未来研究应考虑其他变量,包括医生特征。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Background and Purpose- The 2015 updated US Food and Drug Administration alteplase package insert altered several contraindications. We thus explored clinical factors influencing alteplase treatment decisions for patients with minor stroke. Methods- An expert panel selected 7 factors to build a series of survey vignettes: National Institutes of Health Stroke Scale (NIHSS), NIHSS area of primary deficit, baseline functional status, previous ischemic stroke, previous intracerebral hemorrhage, recent anticoagulation, and temporal pattern of symptoms in first hour of care. We used a fractional factorial design (150 vignettes) to provide unconfounded estimates of the effect of all 7 main factors, plus first-order interactions for NIHSS. Surveys were emailed to national organizations of neurologists, emergency physicians, and colleagues. Physicians were randomized to 1 of 10 sets of 15 vignettes, presented randomly. Physicians reported the subjective likelihood of giving alteplase on a 0 to 5 scale; scale categories were anchored to 6 probabilities from 0% to 100%. A conjoint statistical analysis was applied. Results- Responses from 194 US physicians yielded 156 with complete vignette data: 74% male, mean age 46, 80% neurologists. Treatment mean probabilities for individual vignettes ranged from 6% to 95%. Treatment probability increased from 24% for NIHSS score =1 to 41% for NIHSS score =5. The conjoint model accounted for 25% of total observed response variance. In contrast, a model accounting for all possible interactions accounted for 30% variance. Four of the 7 factors accounted jointly for 58% of total relative importance within the conjoint model: previous intracerebral hemorrhage (18%), recent anticoagulation (17%), NIHSS (13%), and previous ischemic stroke (10%). Conclusions- Four main variables jointly account for only a small fraction (<15%) of the total variance related to deciding to treat with intravenous alteplase, reflecting high variability and complexity. Future studies should consider other variables, including physician characteristics.
引用
- Levine SR, Weingast SZ, Weedon J, et al. To Treat or Not to Treat? Stroke. 2018. PMID: 29976582. doi:10.1161/STROKEAHA.118.020971
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。